Here we take a close look at two upcoming Biotech Stocks which have dominated majority of the news in the Biotech Segment. Xtandi could very well be a game-changer for Medivation. Vivus posted extremely postive results off late but there are reasons to worry if you are an investor of Vivus. Let’s take a closer…
Here we take a close look at three upcoming Biotech Stocks which have dominated majority of the news in the Biotech Segment. All three stocks: Clovis, Biogen & Halozyme have shown some promise in the past and would hope to continue their run of form in the coming months. Let’s take a closer look at…
Here we take a close look at three upcoming Biotech Stocks which have dominated majority of the news in the Biotech Segment. While Sarepta has shown mediocre results in the past few weeks, the stock may be looking for a comeback in the coming times. On the other hand, both Regeneron and Ariad are looking…
AbbVie’s (ABBV) efforts to acquire Ireland-based Shire (SHPG) remains the top news in the biotech market segment. Meanwhile, Gilead Sciences Inc’s (GILD) hepatitis C drug made it to the news yet again thanks to its price tag. Also making it to the news is Clegene Corp. Let’s take a closer look at the three stocks….
It was business as usual for the biotech sector last week with highlights including a deal for the acquisition of product rights, encouraging study results and the granting of breakthrough therapy status for an experimental cancer treatment. Here we take a look at all these news in detail. Regado Biosciences saw its shares plunging 58%…
In this article, we take a look at two stocks which have been in news recently, AcelRx Pharmaceuticals (ACRX) & Nymox Pharmaceuticals (NYMX). Keep an eye out for both these active stocks which have been performing well on the wall street. AcelRx Pharmaceuticals (ACRX) should win FDA approval for the Zalviso pain-killing device on July…
